ライフサイエンスコーパス: apixaban

1 nitiated on VKA compared with rivaroxaban or apixaban.

2 jor bleeding events (MBEs) on rivaroxaban or apixaban.

3 gement of MBEs in patients on rivaroxaban or apixaban.

4 (95% CI, 87 to 94) among patients receiving apixaban.

5 on who received the 5 mg twice daily dose of apixaban.

6 rivaroxaban and of 30% among those receiving apixaban.

7 or life-threatening bleeding associated with apixaban.

8 ant activity of dabigatran, rivaroxaban, and apixaban.

9 or dabigatran, 15 for rivaroxaban, and 4 for apixaban.

10 chronically anticoagulated with warfarin or apixaban.

11 n was 1.89 (95% CI, 1.06-2.72) compared with apixaban.

12 patients with AF initiated on rivaroxaban or apixaban.

13 higher risk of major bleeding compared with apixaban.

14 5.9% receiving enoxaparin, and 2% receiving apixaban.

15 ceiving enoxaparin; and 12 (14.5%) receiving apixaban.

16 IDs on the outcomes of patients treated with apixaban.

17 5% CI, 0.009-0.013], median difference using apixaban 0.025 QALYs [95% CI, 0.024-0.026]).

18 risk in comparison with VKA was observed for apixaban (0.63, 0.51-0.77), edoxaban 60 mg (0.81, 0.67-0

19 were treated with NOACs (rivaroxaban 7,572, apixaban 1,066, and dabigatran 96).

20 een the treatment cohorts (1/103 patients on apixaban [1.0%, 95% CI 0.0-2.9], 4/174 on rivaroxaban [2

21 7 patients; rivaroxaban, 54006 patients; and apixaban, 12886 patients), 4770 major bleeding events oc

22 2%), dabigatran (29%), rivaroxaban (13%), or apixaban (16%) were included with mean age (SD) 72.1 (11

23 Patients receiving apixaban 2.5 mg twice daily exhibited lower apixaban exp

24 Seven patients received apixaban 2.5 mg twice daily for 8 days.

25 Apixaban 2.5 mg twice daily in patients on hemodialysis

26 dl [133 mumol/l]) were randomized to receive apixaban 2.5 mg twice daily or warfarin.

27 The effect of apixaban 2.5 mg twice daily versus warfarin in the >=2 d

28 The effect of apixaban 2.5 mg twice daily versus warfarin on populatio

29 For apixaban 2.5 mg twice daily, the median exposure was 278

30 double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in

31 l trial assessing the efficacy and safety of apixaban (2.5 mg twice daily) for thromboprophylaxis in

32 major bleeding occurred in 3/103 patients on apixaban (2.9%, 95% CI 0.0-6.2), 5/174 on rivaroxaban (2

33 ween the treatment cohorts (1/47 patients on apixaban [2.1%, 95% CI 0.0-6.3], 2/152 on rivaroxaban [1

34 tained data for 795 patients: 150 prescribed apixaban, 326 rivaroxaban, and 319 warfarin.

35 g NOACs (dabigatran 87, rivaroxaban 129, and apixaban 35) before their stroke, 1500 were taking warfa

36 compare 4 therapies: dabigatran 150 mg BID, apixaban 5 mg BID, rivaroxaban 20 mg QD, and warfarin th

37 stantial overlap in the range of exposure to apixaban 5 mg twice daily for patients with or without a

38 Apixaban 5 mg twice daily led to supratherapeutic levels

39 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for at least 12 mo

40 daily steady-state areas under the curve for apixaban 5 mg twice daily were 5512 ng/(mL.h) and 3406 n

41 ), rivaroxaban (20 or 15 mg once daily), and apixaban (5 mg twice daily), respectively, were approved

42 The risk of death was similar with apixaban (54/4624 [1.17%]) and warfarin (49/4530 [1.08%]

43 good adherence was 71% (95% CI, 64%-78%) for apixaban, 60% (95% CI, 52%-68%) for dabigatran, and 70%

44 3 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI,

45 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% con

46 The PT is less sensitive (especially for apixaban); a normal PT may not exclude clinically releva

47 illation) trial, and the treatment effect of apixaban according to NT-proBNP levels.

48 lood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis day

49 A fixed-dose regimen of apixaban alone was noninferior to conventional therapy f

50 Adults prescribed apixaban also had a lower rate of gastrointestinal bleed

51 Apixaban, an oral factor Xa inhibitor administered in fi

52 Apixaban, an oral factor Xa inhibitor that can be admini

53 drug levels of dabigatran, rivaroxaban, and apixaban and coagulation assay results.

54 bleeding," this was lower for treatment with apixaban and dabigatran compared with warfarin.

55 for VTE treatment in the United States, and apixaban and edoxaban are under regulatory consideration

56 coagulants (such as dabigatran, rivaroxaban, apixaban and edoxaban) offer relative efficacy, safety a

57 edian times to GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran.

58 We investigated whether apixaban and rivaroxaban are as effective and safe as wa

59 Apixaban and rivaroxaban are the most commonly prescribe

60 xanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants w

61 d to compare the effectiveness and safety of apixaban and rivaroxaban in prevention of recurrent veno

62 LMWH (Tinzaparin and Dalteparin), and DOAC (Apixaban and Rivaroxaban) and the rate of tumour formati

63 afety between the direct oral anticoagulants apixaban and rivaroxaban, and warfarin in morbidly obese

64 Apixaban and rivaroxaban, both direct-acting oral antico

65 -effectiveness most affected by the price of apixaban and the time horizon.

66 gh 30 days and from 30 days to 6 months with apixaban and VKA and with aspirin and placebo.

67 control and at a rate of 0.33% per year with apixaban and was associated with high short-term morbidi

68 re, anticoagulants (heparins, phenprocoumon, apixaban), and antiplatelet medication.

69 overall, direct OAC (dabigatran/rivaroxaban/apixaban), and multivariable associations between clinic

70 ivaroxaban, 0.28% (95% CrI, 0.14%-0.50%) for apixaban, and 0.89% (95% CrI, 0.66%-1.16%) for the LMWH-

71 DOACs (333 rivaroxaban, 285 dabigatran, 281 apixaban, and 1 edoxaban).

72 with VTE were initiated on VKA, rivaroxaban, apixaban, and dabigatran.

73 e effects of the anti-Xa NOACs (rivaroxaban, apixaban, and edoxaban), and a number of other anticoagu

74 ral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban), many have questioned the need f

75 ACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin f

76 ts (DOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban, provide potential advantages ove

77 0 who received rivaroxaban, six who received apixaban, and one who received edoxaban.

78 DBS to plasma concentrations of dabigatran, apixaban, and rivaroxaban were 1.81, 1.59, and 1.31, res

79 Administration of PCCs after apixaban- and rivaroxaban-related ICH provided a high ra

80 major bleeding rates were low and similar in apixaban- and warfarin-treated patients, regardless of w

81 30 days was 43.3% with no difference between apixaban- and warfarin-treated patients.

82 For rivaroxaban and apixaban, anti-Xa activity is linear (R(2) = 0.89 to 1.0

83 Thus, apixaban appears to be appropriate for patients with atr

84 tudies evaluating the safety and efficacy of apixaban are urgently needed in patients with advanced c

85 mbin (dabigatran) or factor Xa (rivaroxaban, apixaban) are effective and safe alternatives to vitamin

86 ccurred in 74/4560 (1.62%) procedures in the apixaban arm and 86/4454 (1.93%) in the warfarin arm (OR

87 The benefits of apixaban as compared with warfarin are consistent regard

88 The superior efficacy and safety of apixaban as compared with warfarin were similar in patie

89 was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a vi

90 daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) and warfarin in patients w

91 daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) compared with treatment wi

92 Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thrombop

93 randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, fol

94 mbosis or pulmonary embolism to receive oral apixaban (at a dose of 10 mg twice daily for the first 7

95 A recent study demonstrated that apixaban based double therapy reduced bleeding compared

96 characterized the pharmacokinetic profile of apixaban by assessing differences in exposure using nonl

97 might give some assurance to clinicians that apixaban can be an effective and safe therapeutic option

98 trial fibrillation and CrCl 25 to 30 mL/min, apixaban caused less bleeding than warfarin, with even g

99 Among patients with CrCl 25 to 30 mL/min, apixaban caused less major bleeding (hazard ratio, 0.34

100 per 1000 person-years for adults prescribed apixaban compared with 8.0 per 1000 person-years for tho

101 tivariable Cox regression models, the use of apixaban compared with rivaroxaban was associated with d

102 The benefits of apixaban compared with warfarin for stroke or systemic e

103 The efficacy of apixaban compared with warfarin is independent of the NT

104 rly, the benefit of 5 mg twice daily dose of apixaban compared with warfarin on major bleeding in pat

105 periority on efficacy and safety outcomes of apixaban compared with warfarin persists across weight g

106 ts in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and syste

107 Apixaban, compared with warfarin, was associated with fe

108 cebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per millili

109 me and quantify dabigatran, rivaroxaban, and apixaban concentrations on DBS cards.

110 Apixaban consistently reduced stroke, mortality, and ble

111 Apixaban consistently reduced the rate of stroke and sys

112 y of direct oral anticoagulants-rivaroxaban, apixaban, dabigatran, and edoxaban-is noninferior to war

113 w of HIT treatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban).

114 min K antagonist oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban, and rivaroxaban are admi

115 that direct oral anticoagulants (DOACs; ie, apixaban, dabigatran, edoxaban, and rivaroxaban) are at

116 tients with AF were identified who initiated apixaban, dabigatran, or rivaroxaban between October 1,

117 imed to compare 4 oral anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for the

118 ting was used to balance 4 treatment groups (apixaban, dabigatran, rivaroxaban, and warfarin) on 66 b

119 ents with CrCl 25 to 30 mL/min randomized to apixaban demonstrated a trend toward lower rates of majo

120 .10 lifetime QALYs while NCB associated with apixaban did not decrease below 0.10 lifetime QALYs unti

121 bling of serum creatinine, and AKI; however, apixaban did not have a statistically significant relati

122 Dabigatran, rivaroxaban and apixaban differ from warfarin with their fixed oral dose

123 respectively, in Factor Xa-inhibited (250 nM apixaban), diluted platelet rich plasma that had been lo

124 of this study was to describe the effects of apixaban dose adjustment on clinical and pharmacological

125 However, the effects of apixaban dose adjustment to 2.5 mg versus warfarin were

126 administered 6-10 h after the surgery), and apixaban (dose of 2.5 mg twice daily, starting 12-24 h a

127 Apixaban drug concentrations were lower in patients rece

128 ived PCCs for the reversal of rivaroxaban or apixaban due to a MBE.

129 In Phase III trials, rivaroxaban, apixaban, edoxaban (antifactor Xa agents), and dabigatra

130 factor IIa (dabigatran) or Xa (rivaroxaban, apixaban, edoxaban) are available.

131 Insufficient published data for apixaban, edoxaban, and rivaroxaban indicate that furthe

132 ministering rivaroxaban, and 3 administering apixaban) enrolling a total of 57,491 patients were incl

133 Dabigatran, rivaroxaban, and apixaban exhibit variable effects on coagulation assays.

134 apixaban 2.5 mg twice daily exhibited lower apixaban exposure (median area under the concentration t

135 initiating VKA, dabigatran, rivaroxaban, or apixaban for patients aged >/=85 years were 0.81 (95% CI

136 ata from 48286 participants in 4 trials: the Apixaban for Prevention of Acute Ischemic Events 2 (APPR

137 4 multicenter randomized trials (APPRAISE-2 [Apixaban for Prevention of Acute Ischemic Events-2], PLA

138 In a post hoc analysis of ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboemboli

139 The Apixaban for Reduction in Stroke and Other Thromboemboli

140 the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboemboli

141 The prospective, randomized, double-blind Apixaban for Reduction in Stroke and Other Thromboemboli

142 s with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboemboli

143 with the use of amiodarone in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboemboli

144 The Apixaban for Reduction in Stroke and Other Thromboemboli

145 n 14 821 atrial fibrillation patients in the Apixaban for Reduction in Stroke and Other Thromboemboli

146 ntricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboemboli

147 In the Apixaban for Reduction in Stroke and Other Thromboemboli

148 The ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboemboli

149 30 mL/min) enrolled in the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboemboli

150 In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboemboli

151 In the Apixaban for Reduction of Stroke and Other Thromboemboli

152 e the efficacy and safety of rivaroxaban and apixaban for stroke prevention in patients with atrial f

153 with apixaban or warfarin in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With A

154 fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With A

155 (Apixaban for the Prevention of Stroke in Subjects With A

156 Apixaban for the treatment of venous thromboembolism ass

157 prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016

158 dent exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through February 28, 2015.

159 o group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group.

160 eeding occurred in 22 patients (3.8%) in the apixaban group and in 23 patients (4.0%) in the daltepar

161 occurred in 12 of 288 patients (4.2%) in the apixaban group and in 28 of 275 patients (10.2%) in the

162 leeding occurred in 6 patients (2.1%) in the apixaban group and in 3 patients (1.1%) in the placebo g

163 occurred in 32 of 576 patients (5.6%) in the apixaban group and in 46 of 579 patients (7.9%) in the d

164 eeding occurred in 10 patients (3.5%) in the apixaban group and in 5 patients (1.8%) in the placebo g

165 bolism was three per 100 person-years in the apixaban group and seven per 100 person-years in the riv

166 eeding was three per 100 person-years in the apixaban group and six per 100 person-years in the rivar

167 Patients in the apixaban group had a lower incidence of death or hospita

168 te of major hemorrhage among patients in the apixaban group was 2.13% per year compared with 3.09% pe

169 .5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group.

170 .3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group.

171 ccurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in th

172 ding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the co

173 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group.

174 e 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group.

175 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group.

176 For major bleeding, apixaban had a better safety profile than warfarin in al

177 , adults with atrial fibrillation prescribed apixaban had a lower rate of both ischemic stroke or sys

178 Apixaban had a lower risk of association with GI bleedin

179 Compared with VKA, apixaban had either a lower or a similar risk of bleedin

180 Apixaban had the most favorable GI safety profile among

181 of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and ri

182 coagulants (NOACs) (rivaroxaban, dabigatran, apixaban) have been approved by international regulatory

183 s was significantly lower for treatment with apixaban (hazard ratio [HR], 0.35; 95% CI, 0.17-0.72) an

184 varoxaban (HR, 0.55; 95% CrI, 0.35-0.89) and apixaban (HR, 0.31; 95% CrI, 0.15-0.62) were associated

185 05 (82%) pregnancies, dabigatran in 36 (6%), apixaban in 50 (8%), and edoxaban in 23 (4%).

186 The benefits of apixaban in comparison with warfarin are consistent rega

187 le is known about the efficacy and safety of apixaban in relation to renal function changes over time

188 e was less frequent in patients treated with apixaban: in all ARISTOTLE patients, the apixaban/warfar

189 , with only the trials testing dabigatran or apixaban including few patients with 1 stroke risk facto

190 ement of MBEs associated with rivaroxaban or apixaban is effective in most cases and is associated wi

191 Our findings provide evidence that apixaban is efficacious and safe across the spectrum of

192 conclusion the initiation of rivaroxaban and apixaban is increasing significantly over time in patien

193 intervention receiving a P2Y(12) inhibitor, apixaban is preferred over VKA.

194 The 5 mg twice daily dose of apixaban is safe, efficacious, and appropriate for patie

195 ajor extracranial hemorrhage associated with apixaban led to reduced hospitalization, medical or surg

196 On day 9, after a 2.5-mg dose, apixaban levels were monitored hourly during dialysis.

197 effective strategy and that rivaroxaban and apixaban may be associated with the lowest risk for blee

198 rval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage po

199 aller numbers of patients were observed with apixaban (n = 12) and dabigatran (n = 11).

200 The benefit of the 5 mg twice daily dose of apixaban (n = 8665) compared with warfarin (n = 8657) on

201 5 mg/dL or higher-received a reduced dose of apixaban of 2.5 mg twice daily.

202 sess the effect of treatment with aspirin or apixaban on ischemic stroke and major bleeding, in relat

203 nning to take a P2Y(12) inhibitor to receive apixaban or a vitamin K antagonist and to receive aspiri

204 poral trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA

205 Patients started on apixaban or rivaroxaban after newly diagnosed AF were id

206 or pulmonary embolism) who were new users of apixaban or rivaroxaban between Jan 1, 2014, and Dec 31,

207 dition, low-dose anticoagulation with either apixaban or rivaroxaban can be used in the secondary pre

208 gulation strategies are now available, using apixaban or rivaroxaban therapy, beginning in the initia

209 blinded aspirin or placebo and to open-label apixaban or VKA for 6 months.

210 ts with AF were randomized to treatment with apixaban or warfarin in the ARISTOTLE (Apixaban for the

211 gned to receive the 5 mg twice daily dose of apixaban or warfarin, 3966 had 1 dose-reduction criterio

212 d 18201 patients with atrial fibrillation to apixaban or warfarin.

213 18 201 patients with atrial fibrillation to apixaban or warfarin.

214 , 18,201 patients with AF were randomized to apixaban or warfarin.

215 s with atrial fibrillation taking NSAIDs and apixaban or warfarin.

216 h one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were identified between February 2012 a

217 compared dabigatran etexilate, rivaroxaban, apixaban, or edoxaban with VKA therapy in patients with

218 oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) with warfarin, and recorded event

219 observational cohort study of patients with apixaban- or rivaroxaban-related ICH who received PCCs b

220 The superiority of apixaban over warfarin in regard to efficacy and safety

221 ncrease in the initiation of rivaroxaban and apixaban (p-value for increasing trend, p < 0001).

222 We aimed to determine apixaban pharmacokinetics at steady state in patients on

223 of $100 000 per quality-adjusted life year, apixaban provided the greatest absolute benefit while st

224 clinical relevance of reducing ICH by using apixaban rather than warfarin and avoiding concomitant a

225 Apixaban reduced rates of stroke, mortality, and bleedin

226 Apixaban reduced stroke, mortality, and bleeding regardl

227 Apixaban reduced the risk of both outcomes more than war

228 ularisation, while treatment of tumours with Apixaban reduced tumour growth in vivo.

229 e estimated the lifetime NCB of warfarin and apixaban relative to no treatment in quality-adjusted li

230 Apixaban resulted in significantly less ICH (0.33% per y

231 Compared with warfarin, apixaban, rivaroxaban, and dabigatran, costs were $93 06

232 s of randomized trials of DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban) for efficacy and bl

233 nous thromboembolism was similar between the apixaban, rivaroxaban, and warfarin cohorts (1/47 [2.1%,

234 Clinicians may offer thromboprophylaxis with apixaban, rivaroxaban, or LMWH to selected high-risk out

235 I of at least 40 kg/m(2) who were prescribed apixaban, rivaroxaban, or warfarin for either venous thr

236 ratio [RR], 0.68 [95% CI, 0.21 to 2.23]) and apixaban (RR, 0.59 [CI, 0.26 to 1.33]) but increased maj

237 Based on our findings, apixaban seems to be more effective than rivaroxaban in

238 of $100 000 per quality-adjusted life year, apixaban seems to be the optimal anticoagulation strateg

239 coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placeb

240 e of major bleeding episodes was higher with apixaban than with placebo.

241 , and mortality were consistently lower with apixaban than with warfarin across center average TTR an

242 m inhibitors of coagulation (rivaroxaban and apixaban) than dabigatran which is a direct thrombin inh

243 In patients who had received apixaban, the median anti-factor Xa activity decreased f

244 ing the study drug) of patients treated with apixaban therapy and warfarin therapy were not statistic

245 To assess the cost and cost-effectiveness of apixaban therapy compared with warfarin therapy in patie

246 Apixaban therapy for ARISTOTLE-eligible patients with at

247 Apixaban therapy resulted in a significantly lower rate

248 OTLE outcomes, was significantly longer with apixaban therapy vs warfarin therapy (7.94 vs 7.54 quali

249 Apixaban therapy vs warfarin therapy.

250 Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin therapy in pre

251 ectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs.

252 Among the apixaban-treated participants, anti-factor Xa activity w

253 urred after 16/4624 (0.35%) procedures among apixaban-treated patients and 26/4530 (0.57%) procedures

254 ity within 30 days occurred half as often in apixaban-treated patients than in those receiving warfar

255 e effectiveness with no benefit in safety in apixaban-treated patients with normal or mildly impaired

256 significant difference in major bleeding in apixaban-treated patients.

257 e interaction p values for amiodarone use by apixaban treatment effects were not significant.

258 parin once daily (n = 105) or 2.5 mg of oral apixaban twice daily (n = 105) for at least 10 days or u

259 washout period, five patients received 5 mg apixaban twice daily for 8 days.

260 Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily.

261 signed six de novo proteins to bind the drug apixaban; two bound with low and submicromolar affinity.

262 4 patients were included in the cohort (3091 apixaban users and 12 163 rivaroxaban users).

263 men, and mean follow-up was 288 days for new apixaban users and 291 days for new rivaroxaban users.

264 The impact of apixaban versus aspirin on ischemic stroke and major ble

265 re was also no significant heterogeneity for apixaban versus aspirin with regard to major bleeding, w

266 and benefit (ischemic events) over time with apixaban versus VKA and aspirin versus placebo.

267 The safety and efficacy of apixaban versus warfarin appeared not significantly to b

268 The treatment effect of apixaban versus warfarin for the efficacy outcomes of st

269 ients with atrial fibrillation randomised to apixaban versus warfarin in the ARISTOTLE trial and exte

270 e estimated the randomized treatment effect (apixaban versus warfarin) stratified by body weight (<=6

271 Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin.

272 n vs dabigatran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on

273 dabigatran for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients.

274 led Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin

275 Interactions between the effects of apixaban vs warfarin and the presence of 1 or no dose-re

276 t benefits with the 5 mg twice daily dose of apixaban vs warfarin compared with patients without thes

277 The beneficial effects of apixaban vs warfarin on rates of stroke or systemic embo

278 ith apixaban: in all ARISTOTLE patients, the apixaban/warfarin hazard ratio for SSE or death was 0.89

279 Among the drugs studied, the OR for apixaban was 1.23 (95% CI, 0.56-2.73), the OR for dabiga

280 tive, although warfarin would be superior if apixaban was 2% less effective than expected.

281 tion (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2

282 Apixaban was associated with a lower risk of GI bleeding

283 In comparison to warfarin, apixaban was associated with a lower risk of stroke (haz

284 In the DOAC group, apixaban was most frequently used (192 of 201; 95.5%).

285 Apixaban was noninferior to conventional therapy (P<0.00

286 Oral apixaban was noninferior to subcutaneous dalteparin for

287 Apixaban was shown to reduce the risk of major hemorrhag

288 In an atrial fibrillation population, apixaban was superior to aspirin for stroke prevention,

289 Apixaban was the most commonly used agent (n = 36 [69%])

290 Apixaban was the most used OAC at study end (41%), in pa

291 Although apixaban was the optimal strategy in our base case, in p

292 39 351 patients newly prescribed apixaban were propensity score matched to 39 351 patient

293 We report a case of a patient receiving apixaban who developed a spontaneous subdural hematoma a

294 as associated with upstart of rivaroxaban or apixaban with reference to age <65 within the specific a

295 ion; n=18 201), a randomized trial comparing apixaban with warfarin for the prevention of stroke in p

296 We compared the safety of apixaban with warfarin in 269 patients with atrial fibri

297 s in Atrial Fibrillation; n=18 201) compared apixaban with warfarin in patients with atrial fibrillat

298 When comparing apixaban with warfarin, patients who received amiodarone

299 ial Fibrillation (ARISTOTLE) trial comparing apixaban with warfarin.

300 tor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and